The present invention relates to methods and pharmaceutical compositions for the treatment of chronic kidney disease. The inventors used the CMap resources to identify the sesquiterpene lactone parthenolide that was subsequently analyzed for its in vivo capacity to reduce the development of DKD in the type I diabetes mouse model.In particular, the invention relates to a method of treating chronic kidney disease (CKD) in patient in need thereof comprising administering to the patient a therapeutically effective amount of Dimethylaminoparthenolide (DMAPT).